|
| 浙江省11家医院2009~2014年肺癌合并糖尿病患者口服降糖药使用调查 |
| Utilization of Oral Hypoglycemic Drugs in Patients of Lung Cancer with Diabetes in 11 Hospitals of Zhejiang Province During 2009-2014 |
| |
| DOI： |
| 中文关键词: 口服降糖药 用药金额 用药频度 限定日费用 药物利用指数 |
| 英文关键词:Oral hypoglycemic agents Drug consumption DDDs DDC DUI |
| 基金项目:2015年浙江省医药卫生平台计划（编号：2015RCB006） |
|
| 摘要点击次数: 1436 |
| 全文下载次数: 1059 |
| 中文摘要: |
| 摘 要 目的：分析浙江地区11家医院肺癌合并糖尿病患者口服降糖药的使用情况，为肺癌合并糖尿病患者此类药物的临床合理应用提供依据。方法：选取浙江地区11家医院肺癌合并糖尿病患者口服降糖药2009~2014年每年40d的医嘱数据，分析口服降糖药的用药金额、用药频度（DDDs）、限定日费用（DDC）和药物利用指数（DUI）等指标。结果：用药金额占前三位药物的分别是阿卡波糖、格列齐特和瑞格列奈；DDDs排前四位是阿卡波糖、二甲双胍、瑞格列奈和格列美脲；DDC排前四位是罗格列酮、西格列汀、格列齐特和阿卡波糖；12种口服降糖药的DUI值介于0.27~2.94。结论：浙江地区11家医院肺癌合并糖尿病患者口服降糖药的使用存在不合理现象，临床用药时应进一步掌握合理用药指征。 |
| 英文摘要: |
| ABSTRACT Objective: To analyze the usage of oral hypoglycemic drugs in patients of lung cancer with diabetes in 11 hospitals of Zhejiang province, and to provide evidence for clinical rational use of these drugs. Methods:According to the annual 40 days prescriptions data of oral hypoglycemic drugs used by patients of lung cancer with diabetes in 11 hospitals of Zhejiang province from 2009 to 2014, the consumption sum, frequency of utilization (DDDs), defined daily cost (DDC) and drug utilization index (DUI) were analyzed by retrospective research method. Results: The top three drugs of gross earning were acarbose, gliclazide and repaglinide; DDDs in the first row was acarbose, metformin, repaglinide and glimepiride were also on the front line; DDC ranked in the first place is rosiglitazone, then sitagliptin, gliclazid as well as glimepiride; the DUI of 12 kinds of oral hypoglycemic drugs was between 0.27-2.94. Conclusion: The use of oral hypoglycemic drugs in patients of lung cancer with diabetes was not all reasonable in 11 hospitals of Zhejiang province from 2009-2014, rational drug use indications should be better understood by doctors and pharmacists. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
